The US Food and Drug Administration (FDA) has approved bluebird’s Lyfgenia (lovotibeglogene autotemcel) for the treatment of sickle cell disease. Approved for patients aged 12 or older with a history of vaso-occlusive events (VOEs), Lyfgenia is a one-time gene therapy with the potential to resolve VOEs and is custom-designed to treat the underlying cause of the disease. The firm plans to make the therapy available by early 2024.
The sickle cell therapy, Lyfgenia, also known as lovo-cell will be available at the firm’s established network of qualified treatment centers (QTCs). As per the firm, these centers specialize in administering complex gene therapies.